This week, 9 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Medivation, Inc. (MDVN) gets a higher grade this week, advancing from a C last week to a B. Medivation, Inc. acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. The company also gets A’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of MDVN stock.

Galapagos NV Sponsored ADR (GLPG) improves from a C to a B rating this week. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of GLPG stock.

Ophthotech Corp. (OPHT) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of OPHT stock.

Neurocrine Biosciences, Inc. (NBIX) is seeing ratings go up from a C last week to a B this week. Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

Myriad Genetics, Inc. (MYGN) shows solid improvement this week. The company’s rating rises from a C to a B. Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage. The company also gets A’s in earnings growth, earnings momentum, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MYGN stock.

This week, XBiotech, Inc. (XBIT) pushes up from a C to a B rating. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of XBIT stock.

This week, Achillion Pharmaceuticals, Inc.’s (ACHN) ratings are up from a C last week to a B. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

This is a strong week for ARIAD Pharmaceuticals, Inc. (ARIA). The company’s rating climbs to B from the previous week’s C. ARIAD Pharmaceuticals, Inc. is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

The rating of GlycoMimetics, Inc. (GLYC) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of GLYC stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.